Table 2. Relationship between intratumoral HTATIP2 expression/microvessel density and clinicopathological features in sorafenib non-administered cohort 1 after surgery.
| Variables | HTATIP2 densitya | Microvessel densitya | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low (n = 148) | High (n = 149) | P | Low (n = 148) | High (n = 149) | P | |||||
| No. of patients | % | No. of patients | % | No. of patients | % | No. of patients | % | |||
| Age, yearsb | 52.53 ± 11.41 | 51.81 ± 10.64 | .570 | 51.10 ± 9.69 | 53.23 ± 12.13 | .096 | ||||
| Gender | .263 | .263 | ||||||||
| Male | 120 | 81 | 128 | 86 | 120 | 81 | 128 | 86 | ||
| Female | 28 | 19 | 21 | 14 | 28 | 19 | 21 | 14 | ||
| Hepatitis B history | .329 | .048 | ||||||||
| Yes | 130 | 88 | 125 | 84 | 133 | 90 | 122 | 82 | ||
| No | 18 | 12 | 24 | 16 | 15 | 10 | 27 | 18 | ||
| HBeAg | .941 | .081 | ||||||||
| Positive | 56 | 38 | 57 | 38 | 49 | 33 | 64 | 43 | ||
| Negative | 92 | 62 | 92 | 62 | 99 | 67 | 85 | 57 | ||
| ALT, U/Lb | 60.14 ± 72.17 | 53.69 ± 42.18 | .348 | 61.46 ± 75.67 | 52.38 ± 35.27 | .185 | ||||
| AFP, ng/dlb | 7818.98 ± 17501.52 | 3266.13 ± 10386.50 | .007c | 3451.37 ± 10501.47 | 7604.42 ± 17444.87 | .014c | ||||
| Liver cirrhosis | .916 | .472 | ||||||||
| Yes | 114 | 77 | 114 | 77 | 111 | 75 | 117 | 79 | ||
| No | 34 | 23 | 35 | 23 | 37 | 25 | 32 | 21 | ||
| Tumor size, cmb | 6.70 ± 4.53 | 4.45 ± 2.81 | .000c | 4.37 ± 2.44 | 6.77 ± 4.69 | .000c | ||||
| Tumor differentiation | .829 | .082 | ||||||||
| High (Stage I–II) | 105 | 71 | 104 | 70 | 111 | 75 | 98 | 66 | ||
| Low (Stage III–IV) | 43 | 29 | 45 | 30 | 37 | 25 | 51 | 34 | ||
| Intrahepatic metastasis | .002 | .014 | ||||||||
| Yes | 31 | 21 | 12 | 8 | 14 | 9 | 29 | 19 | ||
| No | 117 | 79 | 137 | 92 | 134 | 91 | 120 | 81 | ||
| Tumor encapsulation | .092 | .863 | ||||||||
| Complete | 65 | 44 | 80 | 54 | 73 | 49 | 72 | 48 | ||
| No | 83 | 56 | 69 | 46 | 75 | 51 | 77 | 52 | ||
| Microvascular invasion | .022 | .002 | ||||||||
| Yes | 69 | 47 | 50 | 34 | 46 | 31 | 73 | 49 | ||
| No | 79 | 53 | 99 | 66 | 102 | 69 | 76 | 51 | ||
| TNM stage | .066 | .032 | ||||||||
| I | 13 | 9 | 23 | 15 | 23 | 15 | 13 | 9 | ||
| II | 60 | 40 | 68 | 46 | 69 | 47 | 59 | 39 | ||
| IIIA | 75 | 51 | 58 | 39 | 56 | 38 | 77 | 52 | ||
aThe densities of HTATIP2 and microvessel (CD34) were represented as the index of the integrated optical density/total area and area with positive staining/total area, respectively. The HTATIP2 density (mean ± standard deviation) was 0.0691 ± 0.0703 (median, 0.0457; range, 0.000024–0.389), and the microvessel density was 0.116 ± 0.105 (median, 0.0877; range, 0.00102–0.545).
bStudent's t-test, mean ± standard deviation.
cEqual variances not assumed.
P<0.05 was deemed to be statistically significant.
Abbreviations: HTATIP2, HIV-1 Tat interactive protein 2, 30 kDa; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; TNM, tumor-node-metastasis.